Q80527 (Q80527): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The main objective of the project is to expand the CBR leading R & D in the field of innovative products and processes for the applicant and the whole Synthos capital group. Project planned by Synthos S.A.: “Expansion of the Research and Development Centre of Synthos S.A. in the field of innovative chemical products” includes investment in a licence (including a licence allowing for further research on the development of cationic photoinitiators...) |
(Changed label, description and/or aliases in 1 language: remove_english_label) |
||
| label / en | label / en | ||
Revision as of 12:21, 14 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in Poland financed by DG Regio |
Statements
18,540,567.09 zloty
0 references
52,973,048.82 zloty
0 references
35.0 percent
0 references
1 January 2016
0 references
31 December 2019
0 references
SYNTHOS SPÓŁKA AKCYJNA
0 references
50°2'48.8"N, 19°59'49.9"E
0 references
50°2'1.3"N, 19°15'36.4"E
0 references
Głównym celem projektu jest rozbudowa CBR prowadzącego B+R w zakresie innowacyjnych produktów oraz procesów na potrzeby Wnioskodawcy oraz całej grupy kapitałowej Synthos. Planowany przez Synthos S.A. projekt pn.: "Rozbudowa Centrum Badawczo – Rozwojowego Synthos S.A. w zakresie innowacyjnych produktów chemicznych" obejmuje inwestycję w licencję (w tym m.in. licencję umożliwiającą dalsze prace badawcze nad opracowaniem fotoinicjatorów kationowych czy opracowanie technologii erytrytolu) oraz aktywa materialne na rzecz realizacji ww. celu. (Polish)
0 references
The main objective of the project is to expand the CBR leading R & D in the field of innovative products and processes for the applicant and the whole Synthos capital group. Project planned by Synthos S.A.: “Expansion of the Research and Development Centre of Synthos S.A. in the field of innovative chemical products” includes investment in a licence (including a licence allowing for further research on the development of cationic photoinitiators or the development of erythritol technology) and material assets for the purpose. (English)
14 October 2020
0 references
Identifiers
POIR.02.01.00-00-0127/15
0 references